Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Operating Expenses: 2019-2024

Historic Operating Expenses for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $479.1 million.

  • Beam Therapeutics' Operating Expenses rose 13.03% to $136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 1.94%. This contributed to the annual value of $479.1 million for FY2024, which is 13.55% down from last year.
  • Latest data reveals that Beam Therapeutics reported Operating Expenses of $479.1 million as of FY2024, which was down 13.55% from $554.2 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Operating Expenses peaked at $554.2 million during FY2023, and registered a low of $132.8 million during FY2020.
  • Its 3-year average for Operating Expenses is $477.6 million, with a median of $479.1 million in 2024.
  • In the last 5 years, Beam Therapeutics' Operating Expenses soared by 234.61% in 2021 and then fell by 13.55% in 2024.
  • Beam Therapeutics' Operating Expenses (Yearly) stood at $132.8 million in 2020, then skyrocketed by 234.61% to $444.3 million in 2021, then fell by 10.11% to $399.4 million in 2022, then soared by 38.76% to $554.2 million in 2023, then declined by 13.55% to $479.1 million in 2024.